AURA
Aura BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Primary-source disclosures support a real clinical calendar: mid-2026 NMIBC data, mid-2026 CoMpass enrollment completion, additional 2026 proof-of-concept updates, and a defined 2H 2027 pivotal readout path, while cash of $144.2 million was said to fund operations into Q1 2027 [#8-K-2026-03-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.7.
What can break
Cash runway into Q1 2027 may tighten if trial costs rise or timelines slip.
Momentum
26
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.80
Why
Momentum26 · Δ7d -0.9
Value41 · Δ7d -0.1
Sentiment62 · Δ7d -6.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
26
26% active weight
Current posture
7d trendImproving
Δ7d
-0.9
Δ21d
-1.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
62
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.7
Δ21d
-1.7
Why this grade
Composite grade D. Momentum 25.6 / Value 41.1 / Sentiment 62.2
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$712.68M
Beta
0.46
Shares Out
103.44M
P/E (TTM) · Derived
-3.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.80
Rev YoY
-
EPS YoY
-8.9%
Gross Margin
-
Op Margin
-
Net Debt
-$126.86M
Current Ratio
7.09
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology